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Highlights 
 There is uncertainty whether focusing only on modifiable bleeding factors 
offers better bleeding risk prediction compared to validated bleeding risk 
scores.   
 Relying on bleeding risk assessment using modifiable bleeding risk factors 
alone is an inferior strategy for predicting major bleeding, intracranial 
haemorrhage or extracranial bleeding compared to the HAS-BLED score in 
atrial fibrillation.  
 Our observations support guideline recommendations on using the HAS-BLED 
score for bleeding risk assessment.  
 
ABSTRACT 
 
BACKGROUND  There is uncertainty whether a focus on modifiable bleeding risk 
factors, offers better prediction of major bleeding or intracranial haemorrhage  
compared to other existing bleeding risk scores.   
METHODS Comparison of a score based on numbers of the modifiable bleeding risk 
factors recommended in the 2016 European guidelines (‘European risk score’), to 
other published bleeding risk scores that have been derived and validated in atrial 
fibrillation subjects (HEMORR2HAGES, HAS-BLED, ATRIA and ORBIT) in a large 
hospital-based cohort of Chinese inpatients with atrial fibrillation. 
Results  The European score had modest predictive ability for major bleeding (c- 
index 0.63, 95% CI 0.56-0.69) and intracranial haemorrhage  (0.72, 0.65-0.79), but 
non-significantly (and poorly) predicted extracranial bleeding (0.55, 0.54-0.56, 
p=0.361).  The HAS-BLED score was superior to predict bleeding events compared 
to the European score, with the differences between c-indexes of 0.10-0.12 (Delong 
test, all P <0.05), net reclassification improvement (NRI) values of 13.0%-34.5% (all 
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p<0.05), and integrated discrimination improvement (IDI) values of 0.7%-1.4% (all 
p<0.05). The European score had similar predictive value to other bleeding risk 
schemes (HEMORR2HAGES, ATRIA and ORBIT) for major bleeding and intracranial 
haemorrhage, as reflected by non-significant differences in c-indexes, NRI and IDI (all 
p >0.05).  HEMORR2HAGES and ATRIA were superior to the European score for 
predicting extracranial bleeding.  Decision curve analysis clearly shows that 
HAS-BLED had better net benefit of predicting major bleeding compared to the 
European score. 
Conclusion  Relying on bleeding risk assessment using modifiable bleeding risk 
factors alone is an inferior strategy for predicting atrial fibrillation patients at high 
risk for major bleeding, intracranial haemorrhage or extracranial bleeding. Our 
observations re-affirm the Asian guideline recommendations on using the HAS-BLED 
score for bleeding risk assessment in patients with atrial fibrillation.  
 
Key words:  bleeding, risk stratification, risk factors, HAS-BLED, atrial fibrillation
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INTRODUCTION 
 
Bleeding risk assessment is part of the overall assessment of all patients with atrial 
fibrillation who are started on thromboprophylaxis1. This is particularly relevant in 
Asia, where risks of bleeding and intracranial haemorrhage are higher in Asians 
compared to non-Asians on anticoagulation2. 
 
Many risk factors for bleeding are evident but the most common ones have been 
used to formulate bleeding risk scores3.  The latter are helpful to risk stratify 
patients in an objective way, aiding objective decision-making to identify those 
patients at high risk for bleeding, for example, where triple therapy is being 
considered following presentation with an acute coronary syndrome or stenting. 
The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding 
history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score is 
the most validated score in Asian subjects, and is recommended in Asian 
consensus/guidelines, including the 2016 Chinese Expert consensus on the 
management of atrial fibrillation in the elderly population and 2017 Asia-Pacific 
Heart Rhythm Society (APHRS) consensus guidelines on antithrombotic therapy in 
atrial fibrillation 4 5 6. 
 
Bleeding risks are also influenced by many modifiable bleeding risk factors, and 
attention to these is recommended in all atrial fibrillation patients who are being 
started on anticoagulation.  Of the various scores, the HAS-BLED score was 
designed to ‘flag up’ high risk patients for regular review and follow-up, and to 
draw attention to the modifiable bleeding risk factors, which are contained as 
components of this score7.  Rather than recommending a specific bleeding risk 
score, the 2016 European Society of Cardiology (ESC) guidelines instead directed 
focus to a long-tabulated list of modifiable and partially modifiable bleeding risk 
factors8.  
 
User-friendly clinical assessment tools have been proposed to help the clinicians to 
quantify risk, to help make personalized therapeutic decisions, and not simply rely 
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on guesswork when balancing risks and benefits in everyday ‘real-world’ practice. 
Various studies have investigated various modifiable, non-modifiable and 
biomarker-based bleeding risk factors related to atrial fibrillation8.  
However, whether simply focusing on modifiable bleeding risk factors improves 
clinical decision-making by offering similar (or better) prediction of major bleeding 
or intracranial haemorrhage compared to validated bleeding risk scores has not 
been supported with evidence. On this basis, there is even some uncertainty 
whether a specific bleeding score is really needed.    
 
We previously reported one of the largest Asian cohorts of atrial fibrillation patient 
where bleeding risk assessment was undertaken9. Given the relevance of bleeding 
risk assessment to Asian subjects, we undertook a comparison of a bleeding score 
based on numbers of the ESC guidelines modifiable bleeding risk factors (European 
risk score), to other published bleeding risk scores that have been derived and 
validated in atrial fibrillation subjects. 
 
METHODS 
 
We used the PLA General Hospital electronic health medical records database 
between January 1,1995 to May 30, 2015, which included the patient’s medical 
history, therapeutic procedure, mortality data, laboratory data (Laboratory 
Information System, LIS), and imaging data (Picture Archiving and Communications 
System, PACS). The dataset has been published in detail previously9. 
 
Study population 
The consecutive patients admitted to the PLA General Hospital, Beijing, China, 
were identified with a primary diagnosis of atrial fibrillation or with a major 
co-morbid diagnosis (i.e. Secondary diagnosis) of atrial fibrillation (International 
Classification of Disease, Ninth Revision [ICD-9]/International Classification of 
Disease, tenth Revision [ICD-10] codes 427.3, 427.31/I48) between January 1,1995 
to May 30, 2015. Inclusion criteria also included adult atrial fibrillation population 
age over 18 years, with the diagnosis of ECG or 24h Holter recording. Exclusion 
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criteria included patients age <18 years and outpatients.  In total, 4824 adult 
patients with atrial fibrillation entered the final analysis, excluding 11 inpatients 
aged under 18 years and 2555 patients with readmission(s). 
 
The study was approved by the medical ethics committee of PLA General Hospital 
(Approval No. S2013-064-02).  There was no informed consent given this was the 
registry electronic health medical records study with anonymized data. 
 
Definition of Bleeding risk scores 
Bleeding risk of atrial fibrillation patients was evaluated by the available bleeding 
risk scores (European score for modifiable risk factors, HAS-BLED, HEMORR2HAGES, 
ATRIA, and ORBIT) on admission, and the association between the bleeding risk 
scores and bleeding events on admission and during the in-hospital period was 
analyzed.  
 
European score for modifiable risk factors: hypertension, liable INR or time in 
therapeutic range <60% in patients on vitamin k antagonists, medication 
predisposing to bleeding, such as antiplatelet drugs and non-steroidal 
anti-inflammatory drugs, and excess alcohol (≥8 drinks/week), with 1 point for the 
presence of each risk factor. For the labile INR criterion, we recorded ‘poor 
anticoagulation control’ as assessed by the responsible physician or INR <2.0 at 
presentation. 
 
HAS-BLED score: hypertension (uncontrolled systolic BP>160mm Hg), abnormal 
renal / liver function, stroke, bleeding history, labile INR, elderly (age >65 years), 
drugs (antiplatelets /NSAIDS) /concomitant alcohol (≥8 units/week), with 1 point 
for the presence of each risk factor. Low-intermediate risk: 0–2, high risk: ≥3.   
 
HEMORR2HAGES score: Hepatic or renal disease, Ethanol abuse, Malignancy, Older 
(aged>75), Reduced platelet count, Re-bleeding risk, uncontrolled Hypertension, 
Anaemia, Genetic factors (CYP 2C9 single nucleotide polymorphisms), Excessive fall 
risk, previous Stroke/TIA, 1 point for each risk factor present, & 2 points for 
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previous bleed. Low risk: 0–1, intermediate risk: 2–3, high risk: ≥4.  Genetic 
factors were not routinely measured, so this criterion scored 0, as per previous 
studies. 
 
ATRIA score: anaemia, severe renal disease (estimated glomerular filtration rate, 
eGFR <30 ml/min or dialysis-dependent), age ≥75 years, previous bleed, 
hypertension, with 1 point each for presence of previous bleed or hypertension, 2 
points for age ≥75, and 3 points each for presence of anaemia and renal disease. 
Low risk: 0 to 3, intermediate risk: 4, high risk: 5 to 10. 
 
ORBIT score: 1 point each for Age >74, insufficient kidney function (eGRF < 60 
ml/min/1.73m2) and treatment with any antiplatelet, while 2 points were assigned 
to a positive clinical history for bleeding and the presence of anaemia or abnormal 
hemoglobin (<13 mg/dL for males and <12 mg/dL for females). Low risk: 0 to 2, 
intermediate risk: 3, high risk: ≥ 4. 
 
Definition of bleeding events 
As principal bleeding outcomes, we evaluated major bleeding, intracranial 
haemorrhage and extracranial bleeding. Major bleeding was defined according to 
International Society on Thrombosis and Haemostasis (ISTH) criteria, as follows: (i) 
fatal bleeding; and/or (ii) symptomatic bleeding in a critical area or organ 
(intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, 
or intramuscular with compartment syndrome); and/or (iii) bleeding causing a fall 
in hemoglobin level of 20 g/L or more, or leading to transfusion of two or more 
units of whole blood or red cells10. Intracranial haemorrhage included 
haemorrhagic stroke, subarachnoid haemorrhage, subdural haematoma, and 
epidural haemorrhage, which diagnosed clinically by a neurologist and intracranial 
haemorrhage confirmed by computed tomography (CT) scanning or magnetic 
resonance imaging (MRI). Extracranial bleeding included gastrointestinal bleeding, 
respiratory bleeding, urinary bleeding, subcutaneous hemorrhage resulting in 
anemia, and fundus hemorrhage. 
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Bleeding events and bleeding scores were assessed, combined ICD9/10 codes (e.g. 
intracranial haemorrhage, gastrointestinal bleeding, etc.), laboratory tests (e.g. a 
decrease in hemoglobin level of 20 g/L or more for major bleeding; hemoglobin 
<13 mg/dL for males and <12 mg/dL for females for bleeding risk scores etc.), and 
medical records (e.g. transfusion of two or more units of whole blood or red cells, 
etc.).  
 
Intracranial haemorrhage cases were identified by ICD-9 or ICD-10 codes 
430,431,432; I60.x, I61.x. Other major bleeding events were confirmed by [ICD-10 
codes: I85.0, I98.3 K25–28 (subcodes 0–2 and 4–6 only); K62.5, K92.2, D62.9], etc.  
The detailed definitions of various co-morbidities and risk factors were described 
as the previous study, based on ICD-9 and ICD-10 codes9.   
 
Statistical analysis. 
The predictive ability of the European score for modifiable risk factors, HAS-BLED, 
HEMORR2HAGES, ATRIA, and ORBIT scores for major bleeding, intracranial 
haemorrhage, and extracranial bleeding were evaluated by Receptor Operating 
Characteristic Curve (ROC) analyses, and expressed by C-indexes (95% confidence 
intervals (CI)).     
 
Using the DeLong equality test, the diagnostic accuracy of the available risk scores, 
the differences of areas under the curve (AUC, C-statistic) of European score for 
modifiable risk factors were compared to other bleeding scores for significance.  
We also used the net reclassification improvement (NRI) and integrated 
discrimination improvement (IDI)11 to further verify the predictive ability of 
European score for modifiable risk factors to other bleeding scores for major 
bleeding, intracranial haemorrhage, and extracranial bleeding. Decision curve 
analysis was used to quantify the net benefits related to the use of European score 
for modifiable risk factors, and HAS-BLED for major bleeding, respectively 12. 
 
A two-sided P-value < 0.05 was considered as statistically significant. The 95% 
confidential intervals (CIs) were calculated and the statistical tests were performed 
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using IBM SPSS Statistics, version 22.0 (SPSS Inc), MedCalc 12.6.1.0 (MedCalc 
Software), and the R statistical package and the on-line tutorial developed by 
Vickers et al13.  
 
 
RESULTS 
 
There were 4824 patients with atrial fibrillation (mean age 67 years; 34.9% female) 
during the 20-year observational period. The median (interquartile) in-hospital stay 
was 10(7-16) days. Of these, 481 (10%) were on OAC, with 450 patients taking 
warfarin and 31 taking non-vitamin K antagonist coagulant (NOAC).  Of the 
patients on warfarin, 96% had INR on admission of <2.  
 
After a followup of 246 days, here were 55 (1.14%, 95%CI 0.88%-1.48%) major 
bleedings, 25 (0.52%, 95% CI 0.35%-0.76%) intracranial haemorrhage events, and 
28 (0.51%, 95% CI 0.38%-0.64%) extracranial bleeding events (gastrointestinal 
bleeding, respiratory bleeding, urinary bleeding, subcutaneous hemorrhage 
resulting in anemia, and fundus hemorrhage). 
 
Bleeding events stratified by the bleeding scores  
Major bleeding, intracranial haemorrhage, and extracranial bleeding rates (bleeds 
per 100, 95% CI) associated with bleeding risk schemes were showed in Figure 1. 
With increasing scores of HAS-BLED and HEMORR2HAGES, the rates of major 
bleeding, intracranial haemorrhage, and extracranial bleeding significantly 
increased, as expected (p<0.05).  
 
Predictive ability of bleeding events with different bleeding risk scores  
C-indexes for bleeding events of different bleeding risk scores ranged from 
0.63-0.83 (all p<0.05) (Table 1). Of the tested scores, HAS-BLED had the highest 
c-indexes for major bleeding (0.72) and intracranial haemorrhage (0.83). 
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The European score had modest predictive ability for major bleeding (c- index 0.63, 
95% CI 0.56-0.69) and intracranial haemorrhage (0.72, 0.65-0.79), but 
non-significantly (and poorly) predicted extracranial bleeding (0.55, 0.54-0.56, 
p=0.361) (Table 1).    
 
Comparisons of predictive ability of European score to other bleeding scores 
The HAS-BLED score was superior to predict bleeding events compared to the 
European score, with the differences between c-indexes of 0.10-0.12 (Delong test, 
all P <0.05), net reclassification improvement (NRI) values of 13.0%-34.5% (all 
p<0.05), and integrated discrimination improvement (IDI) values of 0.7%-1.4% (all 
p<0.05) (Table 2, Figure 2A, 2B, 2C).  
 
The European score had similar predictive to other bleeding risk schemes 
(HEMORR2HAGES, ATRIA and ORBIT) for major bleeding and intracranial 
haemorrhage, as reflected by non-significant differences in c-indexes, NRI and IDI 
(all p>0.05).  HEMORR2HAGES and ATRIA were superior to the European score for 
predicting extracranial bleeding (Table 2).  Decision curve analysis showed that 
HAS-BLED had better net benefit of predicting major bleeding compared to the 
European score (Figure 3).  
 
 
DISCUSSION 
In this analysis, we show that relying in bleeding risk assessment using modifiable 
bleeding risk factors alone is an inferior strategy for predicting those atrial 
fibrillation patients at high risk for major bleeding, intracranial haemorrhage or 
extracranial bleeding.  Of the established bleeding risk scores, the HAS-BLED 
score performed best, compared to HEMORR2HAGES, ATRIA and ORBIT. Our 
observations re-affirm the the 2016 Chinese Expert consensus on the management 
of atrial fibrillation in the elderly population and 2017 Asia-Pacific Heart Rhythm 
Society (APHRS) consensus guidelines on antithrombotic therapy in atrial 
fibrillation4 5 6 on using the HAS-BLED score for bleeding risk assessment.  
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While modifiable bleeding risk factors should be addressed in all patients with 
atrial fibrillation irrespective of their bleeding risk strata at every patient contact, 
there should be the appropriate use of a bleeding score to identify those patients 
at high risk for more regular review and follow-up, and to draw attention to 
modifiable bleeding risk factors14.  This approach is important in the healthcare 
settings where electronic health medical records and electronic alerts are used to 
flag up those patients at risk.  Also, clinical pathways are also driven by decision 
aids and protocols, and the availability of a simple practical well-validated bleeding 
risk score to aid objective assessment of bleeding risk that also draws attention to 
modifiable bleeding risk factors, such as HAS-BLED aids decision-making processes. 
 
All the tested bleeding risk scores are clinical scores, and generally have modest 
predictive value for predicting outcomes1.  Bleeding risk is also highly dynamic, 
which can be changed by addressing the modifiable bleeding risk factors that are 
captured within comprehensive scores such as HAS-BLED and HEMORR2HAGES
1.  
In contrast, the ATRIA and ORBIT scores would not capture some reversible 
bleeding risk factors15, and would therefore perform suboptimally compared to 
HAS-BLED, especially where warfarin is being used16.  Similarly, stroke risk in atrial 
fibrillation can be reduced by attention to the modifiable stroke risk factors, such 
as uncontrolled blood pressure. 
The underperformance of the European score may reflect that bleeding events are 
also unlikely to be solely related to modifiable bleeding risk factors.  For example, 
an anticoagulated extremely frail 90-year-old man with atrial fibrillation and 
regular NSAIDs is clearly at high bleeding risk, but has only 1 modifiable bleeding 
risk factor; while an otherwise well 50-year-old man with regular NSAID use who is 
being anticoagulated for an ablation procedure would be at much lower bleeding 
risk, yet would be categorized as ‘1 modifiable bleeding risk factor’.  Thus, 
modifiable and non-modifiable bleeding risk factors need to be considered 
together, as part of the holistic approach to bleeding risk assessment.  
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Limitations 
This study is limited by its dependence on hospital electronic health medical 
records but the codes have been internally validated, as per our previous study17.  
We also studied parameters at baseline, and determined outcomes after a 
observational period of 246 days, but as mentioned above, bleeding risk factors 
may be altered and possibly ameliorated over the follow-up duration.  
Nevertheless, the bleeding risk scores are at best semi-predictive and while they 
may aid decision-making, simple clinical scores do not catch all possible bleeding 
events in an individual patient. Clinicians will still need to do their own assessment 
of the potential risk for bleeding alongside the bleeding risk score used.  Clinical 
judgment is still important when dealing with an individual patient at every contact, 
and should be exercised alongside the bleeding (or stroke) risk scores that are 
applied in practice, or generated by electronic health alerts. 
 
In conclusion, bleeding risk assessment in atrial fibrillation patients only using 
modifiable bleeding risk factors alone is an inferior strategy for predicting those at 
high risk for major bleeding, intracranial haemorrhage or extracranial bleeding. 
Our study supports the recent Chinese consensus and Asia-Pacific Heart Rhythm 
Society guideline recommendations on using the HAS-BLED score for bleeding risk 
assessment in Asian patients with atrial fibrillation. 
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Figure 1 Bleeding events with increasing HAS-BLED, European score, 
HEMORR2HAGES, ATRIA, and ORBIT scores.  
 
Figure 2 Comparison of ROC curves of HAS-BLED, ATRIA, HEMORR2HAGES, ORBIT, 
and European scores for major bleeding events, intracranial haemorrhage, and 
extracranial haemorrhage with Delong test.  
2A Major bleeding events; 2B Intracranial haemorrhage; 2C Extracranial 
haemorrhage 
 
Figure 3 Decision curve analysis comparing HAS-BLED and the European score for 
major bleeding events 
This analysis shows the clinical usefulness of each score based on a continuum of 
potential thresholds for major bleeding (x-axis) and the net benefit of using the 
model to stratify patients at risk (y-axis) relative to assuming that no patient will 
have an event. 
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Table 1 Predictive ability of different bleeding risk scores in 4824 Chinese patients 
with atrial fibrillation 
Major bleeding events (n=55)  C index  95% CI  p  
HAS-BLED 0.72 0.65-0.79 <0.001 
HEMORR2HAGES 0.69 0.62-0.77 <0.001 
ATRIA 0.66 0.58-0.74 <0.001 
ORBIT 0.64 0.56-0.73 <0.001 
European score 0.63 0.56-0.69 0.001 
Intracranial haemorrhage (n=25) C index 95% CI  p  
HAS-BLED 0.83 0.75-0.91 <0.001 
HEMORR2HAGES 0.73 0.61-0.85 <0.001 
European score 0.72 0.65-0.79 <0.001 
ORBIT 0.67 0.54-0.79 <0.001 
ATRIA 0.66 0.54-0.76 <0.001 
Extracranial bleeding(n=28) C index 95% CI  p  
ATRIA 0.69 0.58-0.80 <0.001 
HEMORR2HAGES 0.69 0.68-0.71 0.014 
HAS-BLED 0.67 0.66-0.68 0.002 
ORBIT 0.65 0.64-0.66 0.006 
European score 0.55 0.54-0.56 0.361 
* CI: confidential interval. Major bleeding was defined according to International 
Society on Thrombosis and Haemostasis (ISTH) criteria, as follows: (i) fatal bleeding; 
and/or (ii) symptomatic bleeding in a critical area or organ (intracranial, intraspinal, 
intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with 
compartment syndrome); and/or (iii) bleeding causing a fall in hemoglobin level of 
20 g/L or more, or leading to transfusion of two or more units of whole blood or 
red cells. Intracranial haemorrhage: including haemorrhagic stroke, subarachnoid 
haemorrhage, subdural haematoma, and epidural haemorrhage. Extracranial 
bleeding: including gastrointestinal bleeding, respiratory bleeding, urinary bleeding, 
subcutaneous hemorrhage resulting in anemia, and fundus hemorrhage.  
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Table 2 Comparison of ROC curves of European score and other bleeding risk scores  
 ROC curves analysis  NRI analysis IDI analysis 
Major bleeding events  
Difference between 
areas(95%CI) Z score  p NRI (95%CI)  p IDI (95%CI)  p 
HAS-BLED vs. European score 0.10 (0.04-0.15) 3.326 0.001 0.345(0.234-0.477) <0.00
1 
0.012(0.001-0.08
6) 
0.001 
European score vs. ATRIA 0.03 (-0.05-0.11) 0.775 0.438 0.055(0.019-0.148)  
0.734 
0.004(0.002-0.07
2) 
0.105 
European score vs. 
HEMORR2HAGES 0.06 (-0.01-0.14) 1.730 0.083 
0.200(0.115-0.323) 
0.699 
0.005(0.000-0.12
9) 
0.157 
European score vs. ORBIT 0.02 (-0.07-0.09) 0.419 0.675 0.043(0.016-0.150) 0.840 0.002(0.000-0.12
5) 
0.185 
Intracranial haemorrhage 
Difference between areas 
(95%CI) 
Z 
score  p NRI (95%CI)  p IDI (95%CI)  p 
HAS-BLED vs. European score 0.11 (0.03-0.18) 2.813 0.00
5 
0.130(0.045-0.321) 0.001 0.014(0.001-0.16
5) 
0.00
1 
European score vs. ATRIA 0.04 (-0.07-0.16) 0.724 0.46
9 
-0.043(-0.065-0.13
0) 
0.497 0.001(0.000-0.14
4) 
0.319 
European score vs. 
HEMORR2HAGES 
0.03 (-0.09-0.15) 0.533 0.59
3 
0.062(0.027-0.151) 0.344 0.005(0.000-0.15
2) 
0.213 
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European score vs. ORBIT 0.04 (-0.08-0.15) 0.665 0.50
6 
-0.217(-0.310-0.11
1) 
0.714 0.003(0.000-0.16
9) 
0.335 
Extracranial bleeding 
Difference between areas 
(95%CI) 
Z 
score  p NRI (95%CI)  p IDI (95%CI)  p 
HAS-BLED vs. European score 0.12 (0.04-0.20) 3.054 0.00
2 
0.286(0.152-0.470) <0.00
1 
0.007(0.003-0.13
2) 
0.04
3 
ATRIA vs. European score 0.14 (0.05-0.24) 2.891 0.00
4 
0.297(0.148-0.471) <0.00
1 
0.015(0.002-0.90
8) 
0.00
1 
HEMORR2HAGES vs. European 
score  
0.14 (0.07-0.23) 3.378 0.00
1 
0.357(0.207-0.541) <0.00
1 
0.012(0.001-0.08
7) 
0.00
1 
European score vs. ORBIT 0.09 (-0.01-0.21) 1.175 0.07
5 
-0.143(-0.207-0.09
2) 
0.258 0.004(0.000-0.12
4) 
0.139 
* ROC: receiver operating characteristic. NRI: net reclassification improvement. IDI: integrated discrimination improvement. 
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